Restaino Stefano, Pellecchia Giulia, Arcieri Martina, Bogani Giorgio, Taliento Cristina, Greco Pantaleo, Driul Lorenza, Chiantera Vito, De Vincenzo Rosa Pasqualina, Garganese Giorgia, Sopracordevole Francesco, Di Donato Violante, Ciavattini Andrea, Scollo Paolo, Scambia Giovanni, Vizzielli Giuseppe
Clinic of Obstetrics and Gynecology, "Santa Maria della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy.
PhD School in Biomedical Sciences, Gender Medicine, Child and Women Health, University of Sassari, 07100 Sassari, Italy.
Cancers (Basel). 2025 Jan 8;17(2):186. doi: 10.3390/cancers17020186.
Vulvar carcinoma is an uncommon gynecological tumor primarily affecting older women. Its treatment significantly impacts the quality of life and, not least, aesthetics because of the mutilating surgery it requires.
The management requires a multidisciplinary team of specialists who know how to care for the patient in her entirety, not neglecting psychological aspects and reconstructive surgery. How do the guidelines address multidisciplinarity, team surgical management, passing through preoperative diagnosis, and follow-up in such a challenging rare tumor to treat?
To answer these questions, we compared the main scientific recommendations to identify similarities and differences in diagnostic and therapeutic management to provide an overview of the gaps that there are currently in European and American international recommendations in providing management guidance in a cancer that is both among the rarest and most difficult to manage. In this way, we aim to encourage an update in practices based on the latest scientific evidence.
A review of various international guidelines, some dating back to 2014, shows significant variation in approaches, ranging from initial diagnostic procedures to managing relapses. The most recent guidelines also lacked references to the latest literature, indicating that more robust scientific evidence is needed before new treatments, such as electrochemotherapy for palliation and reconstructive surgery post exenteration, can be widely adopted.
From the systematic comparison of the main international guidelines, a strong heterogeneity emerged in the diagnostic and therapeutic recommendations as well as for the multidisciplinary approach that today is essential. Our work certainly stimulated an update of the main guidelines.
外阴癌是一种罕见的妇科肿瘤,主要影响老年女性。由于其所需的致残性手术,其治疗对生活质量,尤其是美观有重大影响。
该疾病的管理需要一个多学科专家团队,他们要懂得全面照顾患者,不能忽视心理方面和重建手术。在治疗这种具有挑战性的罕见肿瘤时,指南如何涉及多学科性、团队手术管理、术前诊断以及随访?
为回答这些问题,我们比较了主要的科学建议,以确定诊断和治疗管理方面的异同,从而概述欧美国际建议目前在为这种最罕见且最难管理的癌症提供管理指导方面存在的差距。通过这种方式,我们旨在鼓励根据最新科学证据更新实践。
对各种国际指南(有些可追溯到2014年)的审查显示,从初始诊断程序到复发管理,方法存在显著差异。最新的指南也缺乏对最新文献的引用,这表明在诸如姑息性电化学疗法和盆腔廓清术后重建手术等新治疗方法能够被广泛采用之前,需要更有力的科学证据。
通过对主要国际指南的系统比较,在诊断和治疗建议以及当今至关重要的多学科方法方面出现了强烈的异质性。我们的工作无疑推动了主要指南的更新。